0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Perspectives on Safety and Efficacy—The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis

Edward R. Hammond, MD, PhD, MPH1
[+] Author Affiliations
1Medical Evidence and Observational Research Center, AstraZeneca, Gaithersburg, Maryland
JAMA Neurol. 2016;73(9):1052-1054. doi:10.1001/jamaneurol.2016.2284.
Text Size: A A A
Published online

Extract

The emergence of oral-administered small molecules in multiple sclerosis (MS) therapeutics affords patients potential benefits of improved adherence, convenience, and increased effectiveness within a therapeutic area, which has otherwise benefited predominantly from injectable disease-modifying medicines for several decades. Switching from injectable to oral MS treatment may also improve treatment persistence.1 Siponimod (BAF312) is an oral investigational drug, a selective sphingosine 1-phosphate (S1P1,5) receptor modulator,2,3 currently in phase 3 clinical trials for secondary progressive MS (ClinicalTrials.gov Identifier: NCT01665144). Siponimod bears similarities with fingolimod, an S1P1,3,4,5 receptor modulator and first-in-class oral medication approved in the United States in 2010 for relapsing remitting MS (RRMS).4 Because of more selective modulation of S1P receptors, it is important to understand whether the pharmacokinetic profile of siponimod offers improved efficacy and safety.

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

262 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
brightcove.createExperiences();